Neurogenetic Testing Market Outlook (2026–2030) Driven by Growth Factors

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Neurogenetic Testing Market From 2026 To 2030?

The neurogenetic testing market has experienced rapid expansion in recent years. It is projected to climb from $0.7 billion in 2025 to $0.79 billion in 2026, advancing at a compound annual growth rate (CAGR) of 13.5%. The historical rise can be attributed to the early uptake of PCR-based genetic testing, an increasing prevalence of inherited neurological disorders, wider deployment of microarray platforms, the emergence of early diagnostic techniques, and the initial embedding of genetic screening into clinical workflows.

The neurogenetic testing market is set to experience rapid expansion over the next few years, with projections indicating it will reach $1.24 billion in 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This growth in the forecast period is attributable to the increasing demand for next-generation sequencing, the expanding scope of clinical exome sequencing, rising investment in genetic research, the development of advanced molecular diagnostic tools, and the growing adoption of personalized neurological treatment approaches. Major trends anticipated during this period include the rising adoption of whole-exome sequencing technologies, an increasing use of PCR-based neurological genetic tests, the growing implementation of microarray analysis, an expansion of testing for rare neurological genetic disorders, and a growing demand for early diagnosis and predictive testing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Key Drivers Are Affecting The Neurogenetic Testing Market Development?

The increasing occurrence of neurological conditions is anticipated to boost the expansion of the neurogenetic testing market. Neurological disorders are defined as illnesses impacting the nervous system, encompassing the brain, spinal cord, and associated nerves. Their widespread presence stems from factors such as genetic vulnerability, infections, physical injury, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing considerably improves the identification, therapy, and handling of neurological conditions. This is achieved by providing tailored information on genetic risk factors, aiding in treatment choices, and enabling patients and their families to make educated health decisions, ultimately leading to better patient care and results. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, reflecting an accelerating global health burden, neurological disorders now represent the second-leading cause of death and the primary cause of disability worldwide, with more than 40 percent of the global population affected in 2023 and the number of individuals living with brain disease projected to nearly double by 2050. Consequently, the growing occurrence of neurological conditions is expected to fuel the expansion of the neurogenetic testing market.

What Are The Main Segments Within The Neurogenetic Testing Market Segment Structure?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Trends Are Transforming The Neurogenetic Testing Market?

Leading companies in the neurogenetic testing market are developing innovative solutions, such as whole-genome sequencing, to enhance the accuracy and scope of genetic analysis, allowing for more comprehensive and personalized testing for neurological disorders. Whole-genome sequencing (WGS) is a thorough genetic testing method that involves identifying the complete DNA sequence of an individual’s entire genome. For instance, in March 2024, Nucleus Genomics, a US-based company providing genetic analysis, launched a DNA analysis product. This platform aims to empower individuals with a deeper understanding of their genetic predispositions, facilitating informed decisions about their health and well-being. Utilizing cutting-edge technology and expert genetic counseling services, Nucleus Genomics is set to redefine the landscape of genetic testing, bringing the power of whole-genome sequencing directly to individuals and revolutionizing the field of genomic medicine.

Who Are The Companies Participating In The Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Get The Full Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Region Is The Top Contributor To The Neurogenetic Testing Market By Share?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurogenetic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Market Report

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795